Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Legend Biotech's Enterprise Value is $3,257 Mil.
Legend Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-89 Mil. Therefore, Legend Biotech's EV-to-OCF for today is -36.43.
The historical rank and industry rank for Legend Biotech's EV-to-OCF or its related term are showing as below:
LEGN'
s EV-to-OCF Range Over the Past 10 Years
Min: -75.82 Med: -29.67 Max: -12.31
Current: -36.43
During the past 8 years, the highest EV-to-OCF of Legend Biotech was -12.31. The lowest was -75.82. And the median was -29.67.
LEGN's EV-to-OCF is ranked better than 88.52% of 1411
companies
in the Biotechnology industry
Industry Median: -3.63
vs LEGN: -36.43
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Legend Biotech's PE Ratio (TTM) for today is calculated as:
Legend Biotech's share price for today is $20.35.
Legend Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Legend Biotech EV-to-OCF Related Terms
Legend Biotech EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Legend Biotech's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Legend Biotech's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Legend Biotech's EV-to-OCF falls into.
Legend Biotech's current Enterprise Value is $3,257 Mil.
Legend Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech (LEGN) has a EV-to-OCF of -36.43 as of Aug. 16, 2026. According to the industry distribution chart, Legend Biotech ranks #162 out of 1411 companies in the Biotechnology industry, placing it in the top 11.5%.
Is Legend Biotech's EV-to-OCF too high?
Legend Biotech's current EV-to-OCF is -36.43. Based on the distribution chart, Legend Biotech ranks #162 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Legend Biotech has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's EV-to-OCF compare to TNGX and ACAD?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #162 out of 1411 companies for EV-to-OCF. This places Legend Biotech in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Legend Biotech's current EV-to-OCF is -36.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Significantly Undervalued. The stock's GF Value™ is $79.13, compared to a current price of $20.35 — trading 74.3% below its estimated fair value. The current EV-to-OCF is -36.43. Legend Biotech's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Legend Biotech (LEGN), the current EV-to-OCF is -36.43 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (LEGN) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of $20.35 is trading 74.3% below its estimated GF Value™ of $79.13.
GuruFocus considers Legend Biotech to be Significantly Undervalued.
Key valuation signals for LEGN:
EV-to-OCF: -36.43
GF Value™: $79.13 vs. price of $20.35 (74.3% below fair value)
No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
74GF Score
Get the complete analysis for LEGN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEGN has been successfully added to your 
